Officer of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL), recently purchased 20,000 shares of the company's common stock. The shares were acquired at a price of $2.2828 each, totaling $45,656.

Paul Andrea, Chief Legal Officer at Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL), recently reported a sale of company stock ...

The move is part of a strategic restructuring aimed at getting azenosertib to the market for patients with gynecological ...

Leerink Partnrs issued their Q3 2025 earnings estimates for Zentalis Pharmaceuticals in a report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens forecasts that the company will ...

SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small ...

In a report released on January 29, Andrew Berens from Leerink Partners maintained a Hold rating on Zentalis Pharmaceuticals (ZNTL – Research ...

Azenosertib Clinical Results ZN-c3-001 ZN-c3-001 is a Phase 1, dose-escalation study that evaluated azenosertib monotherapy in solid tumors across continuous and intermittent dosing schedules.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Oric Pharmaceuticals (ORIC – Research Report) ...